Format

Send to

Choose Destination
Biol Open. 2018 Jul 23;7(7). pii: bio032839. doi: 10.1242/bio.032839.

Dynamic nuclear envelope phenotype in rats overexpressing mutated human torsinA protein.

Author information

1
Institute for Medical Genetics and Applied Genomics, University of Tuebingen, Calwerstr. 7, 72076 Tuebingen, Germany.
2
Centre for Rare Diseases, University of Tuebingen, Calwerstr. 7, 72076 Tuebingen, Germany.
3
Core Facility Transgenic Animals, University Hospital Tuebingen, Otfried-Mueller-Str. 27, 72076 Tuebingen, Germany.
4
Agilent Technologies, 5301 Stevens Creek Blvd, Santa Clara, CA 95051, USA.
5
Department of Dermatology, University of Tuebingen, Liebermeisterstr. 25, 72076 Tuebingen, Germany.
6
Institute for Medical Genetics and Applied Genomics, University of Tuebingen, Calwerstr. 7, 72076 Tuebingen, Germany hoa.nguyen@med.uni-tuebingen.de.

Abstract

A three-base-pair deletion in the human TOR1A gene is causative for the most common form of primary dystonia: the early-onset dystonia type 1 (DYT1 dystonia). The pathophysiological consequences of this mutation are still unknown. To study the pathology of the mutant torsinA (TOR1A) protein, we have generated a transgenic rat line that overexpresses the human mutant protein under the control of the human TOR1A promoter. This new animal model was phenotyped with several approaches, including behavioral tests and neuropathological analyses. Motor phenotype, cellular and ultrastructural key features of torsinA pathology were found in this new transgenic rat line, supporting that it can be used as a model system for investigating the disease's development. Analyses of mutant TOR1A protein expression in various brain regions also showed a dynamic expression pattern and a reversible nuclear envelope pathology. These findings suggest the differential vulnerabilities of distinct neuronal subpopulations. Furthermore, the reversibility of the nuclear envelope pathology might be a therapeutic target to treat the disease.

KEYWORDS:

DYT1 dystonia; Nuclear envelope; Pathology; Rat; TorsinA; Transgenic

Conflict of interest statement

Competing interestsThe authors declare no competing or financial interests.

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center